Hims & Hers Planning to Sell Compounded Peptides

Hims & Hers planning to sell compounded peptides

Hims & Hers Health is planning to sell compounded peptides, the company said in a Monday earnings call. The company’s CEO, Andrew Dudum, said in the earnings call that it was “currently developing a best-in-class peptides experience, including U.S. manufactured products, clinical-led guidance, and ongoing blood testing.” Dudum said in the call that the company...

Is Hims The Next Big Name In Peptides?

Hims stock inched lower Tuesday, recovering from a late-Monday dive, as the telehealth giant seemingly moves closer to the peptide segment.

Hims & Hers' shift to branded obesity drugs drives wider quarterly loss

Hims 'able to move extremely quickly' if FDA greenlights six wellness peptides, CEO says

Hims & Hers is laying the groundwork to offer access to six banned consumer wellness peptides, should the FDA lift restrictions that prevent compounding pharmacies from making them. During its second-quarter earnings ...

Hims & Hers stock drops 7% despite higher guidance: what went wrong?

Shares of Hims & Hers Health fell more than 7% in premarket trading on Tuesday after the telehealth company reported a wider-than-expected second-quarter loss, as investments in branded GLP-1 weight-loss treatments and international expansion weighed on profitability. The company reported a net loss of 37 cents per share for the quarter, compared with analysts' expectations for a loss of 1 cent per share, according to LSEG data. The weaker botto…